Medical Oncology Department, Hospital de Mataró, Carretera de la Cirera, s/n, 08304 Mataró, Barcelona, Spain.
Crit Rev Oncol Hematol. 2013 Nov;88(2):375-86. doi: 10.1016/j.critrevonc.2013.05.017. Epub 2013 Jul 1.
The cornerstone of treatment for early-stage non-small cell lung cancer (NSCLC) has been surgical resection. In the last five years two phase III trials have provided evidence of adjuvant platinum-based chemotherapy for completely resected stage II-IIIA patients. We review the evidence supporting adjuvant therapy in early-stage NSCLC; we discuss new issues surrounding adjuvant therapy such as treatment in the elderly-unfit population, treatment toxicity and its influence on outcomes, the importance of histology and gender in adjuvant treatment; and we discuss the future landscape of early-stage NSCLC research, namely, therapeutic strategies exploiting pharmacogenomic and gene-expression profiling, in an attempt to customize the treatment.
早期非小细胞肺癌 (NSCLC) 的治疗基石一直是手术切除。在过去的五年中，两项 III 期临床试验为完全切除的 II 期-IIIA 期患者提供了辅助铂类化疗的证据。我们回顾了支持早期 NSCLC 辅助治疗的证据；我们讨论了辅助治疗中一些新的问题，如老年体弱人群的治疗、治疗毒性及其对结果的影响、组织学和性别在辅助治疗中的重要性；我们还讨论了早期 NSCLC 研究的未来前景，即利用药物基因组学和基因表达谱进行治疗策略，试图定制治疗。
